Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation

被引:1
|
作者
Zhang, Ran [1 ]
Lu, Xuan [2 ]
Tang, Liang V. [2 ]
Wang, Huafang [2 ]
Yan, Han [2 ]
You, Yong [2 ]
Zhong, Zhaodong [2 ]
Shi, Wei [2 ]
Xia, Linghui [2 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Inst Hematol, Tongji Med Coll, Wuhan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
haploidentical hematopoietic stem cell transplantation; graft composition; G-CSF-mobilized BM cells; G-CSF-mobilized PBSCs; total nucleated cells; MOBILIZED PERIPHERAL-BLOOD; PRIMED BONE-MARROW; POSTTRANSPLANT CYCLOPHOSPHAMIDE; CONDITIONING REGIMEN; LEUKEMIA; OUTCOMES; SURVIVAL;
D O I
10.3389/fimmu.2022.993419
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mobilized PBSCs in HLA4/6-matched transplantation. On the one hand, we wanted to explore the effect of harvests (CD34+ cells and TNCs dosages) on transplantation outcome in the context of haplo-HSCT no matter HLA4/6 or HLA3/6-matched setting. On the other hand, for patients using G-CSF-mobilized BM and PBSCs combination in HLA3/6-matched setting, we attempted to analyze whether TNCs or CD34+ cells from G-CSF-mobilized BM or G-CSF-mobilized PBSCs play the most paramount role on transplantation prognosis. Collectively, patients with hematologic malignancies receiving G-CSF-primed BM and PBSCs harvests had comparable consequences with patients only receiving G-CSF-mobilized PBSCs. Moreover, when divided all patients averagely according to the total amount of transfused nucleated cells, 3-year TRM of the intermediate group (13.06-18.05x10(8)/kg) was only 4.9%, which was remarkably reduced when compared to lower and higher groups with corresponding values 18.3%, 19.6% (P=0.026). The 3-year probabilities of OS and DFS of this intermediate group were 72.6% and 66.5%, which were slightly improved than the lower and higher groups. Most importantly, these data suggest that the transfused nucleated cells from G-CSF-primed BM above than 5.20x10(8)/kg could achieve remarkably lower TRM in haplo-HSCT receiving G-CSF-mobilized BM and PBSCs harvests. These encouraging results suggested that we could improve the efficacy of haplo-HSCT by adjusting the component and relative ratio of transfused graft cells. Nevertheless, the above findings should be confirmed in a randomized prospective comparative research with adequate follow-up.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Cord blood versus haploidentical stem cell transplantation for hematological malignancies
    Kekre, Natasha
    Antin, Joseph H.
    SEMINARS IN HEMATOLOGY, 2016, 53 (02) : 98 - 102
  • [2] Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation
    Tian, Zhengqin
    Man, Qihang
    Yang, Yixin
    Guan, Hexian
    Wang, Ying
    Luo, Rongmu
    Wang, Jingbo
    ANNALS OF HEMATOLOGY, 2024, 103 (05) : 1729 - 1736
  • [3] Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients
    Pagliardini, Thomas
    Harbi, Samia
    Furst, Sabine
    Castagna, Luca
    Legrand, Faezeh
    Faucher, Catherine
    Granata, Angela
    Weiller, Pierre-Jean
    Calmels, Boris
    Lemarie, Claude
    Chabannon, Christian
    Bouabdallah, Reda
    Mokart, Djamel
    Vey, Norbert
    Blaise, Didier
    Devillier, Raynier
    BONE MARROW TRANSPLANTATION, 2019, 54 (07) : 1067 - 1076
  • [4] A single-center experience of haploidentical stem cell transplantation in hematological malignancies
    Malkan, Umit Yavuz
    Goker, Hakan
    Demiroglu, Haluk
    Tekin, Fatma
    Akdemir, Buket
    Karakulak, Elifcan Aladg
    Sayinalp, Nilgun
    Haznedaroglu, Ibrahim Celalettin
    Ozcebe, Osman Ilhami
    Buyukasik, Yahya
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2023, 53 (01) : 352 - 359
  • [5] Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies
    Gonzalez-Llano, Oscar
    Eugenio Gonzalez-Lopez, Elias
    Carolina Ramirez-Cazares, Ana
    Rene Marcos-Ramirez, Edson
    Jose Ruiz-Arguelles, Guillermo
    Gomez-Almaguer, David
    PEDIATRIC BLOOD & CANCER, 2016, 63 (11) : 2033 - 2037
  • [6] Unmanipulated haploidentical transplantation for adult patients with hematological malignancies
    Ruggeri, Annalisa
    Santoro, Nicole
    HEMASPHERE, 2019, 3 : 170 - 172
  • [7] T cell replete-haploidentical second hematopoietic stem cell transplantation for primary graft failure in pediatric patients with hematologic malignancies
    Mochizuki, Kazuhiro
    Sano, Hideki
    Akaihata, Mitsuko
    Kobayashi, Shogo
    Waragai, Tomoko
    Ohara, Yoshihiro
    Takahashi, Nobuhisa
    Ito, Masaki
    Ikeda, Kazuhiko
    Ohto, Hitoshi
    Kikuta, Atsushi
    PEDIATRIC TRANSPLANTATION, 2017, 21 (07)
  • [8] The Impact of Graft Composition on Clinical Outcomes in Pediatric Patients Undergoing Unmanipulated HLA-Mismatched/Haploidentical Hematopoietic Stem Cell Transplantation
    Liu, Dai-Hong
    Zhao, Xiao-Su
    Chang, Ying-Jun
    Liu, Yan-Kai
    Xu, Lan-Ping
    Chen, Huan
    Han, Wei
    Chen, Yu-Hong
    Wang, Yu
    Huang, Xiao-Jun
    PEDIATRIC BLOOD & CANCER, 2011, 57 (01) : 135 - 141
  • [9] Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis
    Yang, Bo
    Yu, Ruili
    Cai, Lili
    Guo, Bin
    Chen, Hongfei
    Zhang, Haomin
    He, Peifeng
    Lu, Xuechun
    BONE MARROW TRANSPLANTATION, 2019, 54 (01) : 99 - 122
  • [10] Advances in haploidentical stem cell transplantation for hematologic malignancies
    Montoro, Juan
    Sanz, Jaime
    Sanz, Guillermo F.
    Sanz, Miguel A.
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1766 - 1775